title: [Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma].
abstract: OBJECTIVE
  To evaluate the impact of sequential targeted therapy including vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) and everolimus on progression-free survival (PFS) in metastatic renal carcinoma.
  
  
  METHODS
  A total of 17 patients of metastatic renal cell carcinoma from Department of Kidney Cancer and Melanoma, Peking University Cancer Hospital since January 2008 until April 2014 were enrolled into this retrospective study. They took at least 2 lines of VEGFR-TKIs and everolimus. The data of total PFS and PFS of each therapy were extracted and analyzed.
  
  
  RESULTS
  The sequential targeted therapies affected total PFS (18.0 vs 46.0 months, Kaplan-Meier survival analysis, P = 0.015) with a statistical dislike of VEGFR-TKI/VEGFR-TKI/mTOR inhibitor (TTM) over VEGFR-TKI/mTOR inhibitor/VEGFR-TKI (TMT) , HR = 5.44 (Cox regression analysis, 95% CI 1.18-25.06).
  
  
  CONCLUSIONS
  TMT may prolong the total PFS of metastatic renal cell carcinoma.
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Kidney Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Si
authors.affiliation: Department of Clinical Oncology, Peking University Health Science Center, Beijing 100191, China.
authors.forename: Xue
authors.initials: X
authors.lastname: Bai
authors.forename: Lili
authors.initials: L
authors.lastname: Mao
authors.forename: Xuan
authors.initials: X
authors.lastname: Wang
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Chi
authors.forename: Chuanliang
authors.initials: C
authors.lastname: Cui
authors.forename: Xinan
authors.initials: X
authors.lastname: Sheng
authors.forename: Bixia
authors.initials: B
authors.lastname: Tang
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Kidney Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, China. Email: guoj307@126.com.
authors.forename: Jun
authors.initials: J
authors.lastname: Guo
mesh_terms: D000970:Antineoplastic Agents; D002292:Carcinoma, Renal Cell; D018572:Disease-Free Survival; D000068338:Everolimus; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms; D047428:Protein Kinase Inhibitors; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus